Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors.
暂无分享,去创建一个
S. Kennel | S. Mirzadeh | T. Lankford | L. Chappell | M. Brechbiel | M. Stabin | I. Davis | K. Dadachova
[1] L. Chappell,et al. Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications. , 2000, Bioconjugate chemistry.
[2] L. Chappell,et al. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. , 1999, Nuclear medicine and biology.
[3] R. McLendon,et al. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. , 1999, International journal of radiation oncology, biology, physics.
[4] S. Kennel,et al. Improved in vivo stability of actinium-225 macrocyclic complexes. , 1999, Journal of medicinal chemistry.
[5] S. Kennel,et al. Comparison of 225actinium chelates: tissue distribution and radiotoxicity. , 1999, Nuclear medicine and biology.
[6] S. Kennel,et al. Radioimmunotherapy of micrometastases in lung with vascular targeted213Bi , 1999, British Journal of Cancer.
[7] S. Kennel,et al. Treatment of lung tumor colonies with 90Y targeted to blood vessels: comparison with the alpha-particle emitter 213Bi. , 1999, Nuclear medicine and biology.
[8] J. Humm,et al. Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.
[9] S. Kennel,et al. Vascular targeted radioimmunotherapy with 213Bi-An α-particle emitter , 1998 .
[10] C. Wai,et al. Carboxylate-derived calixarenes with high selectivity for actinium-225 , 1998 .
[11] S. Kennel,et al. Optimizations of Radiolabeling of Immunoproteins with 213Bi , 1997 .
[12] Wendy S. Becker,et al. Radioimmunotherapy of solid tumors: a review "of mice and men". , 1997, Hybridoma.
[13] S. Kennel,et al. Vascular Targeting for Radioimmunotherapy with 213Bi , 1997 .
[14] C. Apostolidis,et al. The feasibility of 225 Ac as a source of α‐particles in radioimmunotherapy , 1993 .
[15] S. Mirzadeh,et al. The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .
[16] S. Kennel,et al. Thrombomodulin is preferentially expressed in Balb/c lung microvessels. , 1992, The Journal of biological chemistry.
[17] M. Brechbiel,et al. Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter , 1992 .
[18] S. Kennel,et al. Rat monoclonal antibody distribution in mice: an epitope inside the lung vascular space mediates very efficient localization. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[19] S. Mirzadeh,et al. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. , 1990, Bioconjugate chemistry.
[20] L. Huang,et al. Monoclonal antibody targeting of liposomes to mouse lung in vivo. , 1989, Cancer research.
[21] Krishan Kumar,et al. Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .
[22] S. Kennel,et al. Quantitation of a murine lung endothelial cell protein, P112, with a double monoclonal antibody assay. , 1988, Laboratory investigation; a journal of technical methods and pathology.
[23] C. Meares. Chelating agents for the binding of metal ions to antibodies. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[24] R. Delgado,et al. Metal complexes of cyclic tetra-azatetra-acetic acids. , 1982, Talanta.
[25] L. F. Fajardo,et al. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. , 1972, Journal of the National Cancer Institute.